|Dr. Scott Koenig||CEO, Pres & Director||905.44k||466k||1952|
|Mr. James Karrels||Sr. VP, CFO & Sec.||533.25k||145.22k||1967|
|Dr. Ezio Bonvini||Sr. VP of Research & Chief Scientific Officer||575.14k||N/A||1954|
|Mr. Eric Blasius Risser||Sr. VP of Bus. Devel. & Portfolio Management and Chief Bus. Officer||531.38k||198.9k||1973|
|Anna Krassowska Ph.D.||VP of Investor Relations & Corp. Communications||N/A||N/A||N/A|
|Mr. Jeffrey Stuart Peters||VP & Gen. Counsel||N/A||N/A||1971|
|Dr. Thomas M. Spitznagel||Sr. VP of BioPharmaceutical Devel. & Manufacturing||N/A||N/A||1967|
|Dr. Stephen L. Eck||Sr. VP of Clinical Devel. & Chief Medical Officer||N/A||N/A||1955|
|Ms. Lynn Cilinski||VP, Controller & Treasurer||N/A||N/A||1958|
MacroGenics, Inc., a biopharmaceutical company, discovers and develops antibody-based therapeutics for the treatment of cancer in the United States. Its pipeline of immuno-oncology product candidates includes Margetuximab, a monoclonal antibody, which is in Phase III clinical trial that targets HER2-expressing tumors, such as various breast and gastroesophageal cancers. The company is also developing Flotetuzumab, a DART molecule that recognizes CD123 and CD3 for treating acute myeloid leukemia; MGA012, an investigational monoclonal antibody targeting PD-1; MGD013, a monoclonal antibody that targets the PD-1 and lymphocyte-activation gene 3; MGD019, a monoclonal antibody that targets the immune checkpoints PD-1 and cytotoxic T-lymphocyte-associated protein 4; and Enoblituzumab, a monoclonal antibody that targets B7-H3. In addition, the company is developing combination of MGD009 and MGA012; MGC018, an antibody drug conjugate, which targets solid tumors expressing B7-H3; and MGD014, a DART molecule that targets envelope protein of human immunodeficiency virus infected cells and T cells. It has strategic collaborations with Incyte Corporation; Zai Lab Limited; and I-Mab Biopharma. MacroGenics, Inc. was founded in 2000 and is headquartered in Rockville, Maryland.
MacroGenics, Inc.’s ISS governance QualityScore as of 6 October 2020 is 7. The pillar scores are Audit: 2; Board: 5; Shareholder rights: 7; Compensation: 9.